Global Exosome Trials
暫譯: 全球外泌體臨床試驗

Weiss, Jeffrey N.

Global Exosome Trials
  • 出版商: Springer
  • 出版日期: 2026-01-03
  • 售價: $5,010
  • 貴賓價: 9.5 折 $4,760
  • 語言: 英文
  • 頁數: 375
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 3031964195
  • ISBN-13: 9783031964190

    • 海外代購書籍(需單獨結帳)

相關主題

商品描述

This book offers a comprehensive review of the global exosome trials in neurology and ophthalmology, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. The book begins with an introduction to exosomes and exosome therapy, which involves the injection or infusion of exosomes, making it less invasive than traditional gene therapy, which involves the introduction, removal, or alteration of genetic material. Subsequent chapters discuss neurologic exosome therapy trials and ophthalmic exosome therapy trials. The book covers topics such as Alzheimer's Disease, back pain, cancer, dementia, neuralgia, dry eyes, diabetic retinopathy, and macular hole. Chapters will examine currently recruiting studies as well as soon-to-be recruiting studies.

Global Exosome Trials in Neurology and Ophthalmology will be a valuable resource for neurologists, neurosurgeons, ophthalmologists, related and allied physicians, PhDs, and researchers.

商品描述(中文翻譯)

這本書提供了對全球神經學和眼科領域的外泌體（exosome）臨床試驗的全面回顧，這些試驗已在美國國立衛生研究院網站 clinicaltrials.gov 上註冊。clinicaltrials.gov 是全球最大的研究研究列表。書中提供了研究標題、來源國以及臨床試驗編號，以便讀者更容易找到研究並獲取進一步的信息。書籍開始介紹外泌體及外泌體療法，這種療法涉及外泌體的注射或輸注，與傳統基因療法相比，這種方法侵入性較小，傳統基因療法涉及基因材料的引入、去除或改變。隨後的章節將討論神經學外泌體療法試驗和眼科外泌體療法試驗。書中涵蓋的主題包括阿茲海默症（Alzheimer's Disease）、背痛、癌症、癡呆、神經痛、乾眼症、糖尿病視網膜病變和黃斑孔。各章將檢視目前正在招募的研究以及即將招募的研究。

《全球神經學和眼科的外泌體試驗》將成為神經科醫生、神經外科醫生、眼科醫生、相關及相關領域的醫生、博士及研究人員的重要資源。

作者簡介

Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.

Dr. Weiss is the author of more than 100 publications, including 30 books, holds more than 23 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss' inventions worldwide.

Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment to successfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.

Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov

作者簡介(中文翻譯)

傑佛瑞·N·韋斯醫生曾任波士頓喬斯林糖尿病中心視網膜外科主任，哈佛醫學院教職員，並擔任麻省理工學院的訪問科學家。

韋斯醫生是超過100篇出版物的作者，包括30本書籍，擁有超過23項美國及外國專利，並曾擔任多本學術期刊的審稿人。他曾擔任訪問教授，進行手術，並在國內外講授課程。韋斯醫生也是兩家公司的創辦人，Ocular Research Associates Inc. 和 Micron Ophthalmic, Inc.，這些公司在全球製造和銷售韋斯醫生的發明。

韋斯醫生是首位發明設備並開發技術以安全地進行視網膜血管插管的醫生。這項手術仍然是嚴重眼部中風患者的唯一選擇。他也是首位報告使用高壓氧治療成功治療乾性年齡相關性黃斑變性及長期中央視網膜動脈阻塞的醫生。

韋斯醫生於2010年進行了首例視網膜幹細胞手術，並擔任幹細胞眼科治療研究 I/II 的主要研究者，這是全球最大的視網膜和視神經幹細胞研究，以及神經幹細胞治療研究。這些研究已獲得機構審查委員會（IRB）批准，並在美國國立衛生研究院（NIH）註冊，且列在 ClinicalTrials.gov 上。

類似商品